03/27/23 7:00 AMNasdaq : TNGX earningsTango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology companyRHEA-AIpositive
03/14/23 8:11 PMNasdaq : TNGX clinical trialTango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingTango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida. AbstractRHEA-AIneutral
03/10/23 10:15 PMNasdaq : TNGX Tango Therapeutics Announces Limited Exposure to Silicon Valley BankTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported that it is aware of the current situation affecting Silicon Valley BankRHEA-AIneutral
03/06/23 7:00 AMNasdaq : TNGX Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective March 1, 2023, the Compensation Committee of TangoRHEA-AIvery positive
03/01/23 7:00 AMNasdaq : TNGX conferencesTango Therapeutics to Participate in Upcoming Investor ConferencesTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer ofRHEA-AIneutral
02/28/23 7:00 AMNasdaq : TNGX managementTango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and DevelopmentTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Adam Crystal, M.D., Ph.D. as President ofRHEA-AIvery positive
02/02/23 7:00 AMNasdaq : TNGX conferencesTango Therapeutics to Participate in Upcoming Investor ConferencesTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer ofRHEA-AIneutral
01/25/23 7:00 AMNasdaq : TNGX Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business UpdatesTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,RHEA-AIvery positive
11/10/22 7:00 AMNasdaq : TNGX earningsTango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France – – TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment of STK11-mutant cancers – – TNG348 declared as a USP1RHEA-AIneutral
11/07/22 7:00 AMNasdaq : TNGX conferencesTango Therapeutics to Participate in Upcoming Investor ConferencesTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer ofRHEA-AIneutral